Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,349 JPY | +0.23% | +0.02% | +2.78% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.78% | 3.13B | C | ||
+27.44% | 76.86B | C+ | ||
-1.87% | 24.07B | C+ | ||
+6.60% | 9.01B | C | ||
+11.89% | 8.67B | B | ||
-23.37% | 7.58B | B- | ||
+14.96% | 5.17B | B- | ||
+2.06% | 4.12B | B | ||
-7.61% | 3.87B | B- | ||
-2.10% | 3.63B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 7459 Stock
- Ratings MediPal Holdings Corporation